Safety and Pharmacokinetics of Islatravir in Individuals with Severe Renal Insufficiency

Islatravir (MK-8591) is a high-potency reverse transcriptase translocation inhibitor in development for the treatment of HIV-1 infection. Data from preclinical and clinical studies suggest that ~30% to 60% of islatravir is excreted renally and that islatravir is not a substrate of renal transporters. ABSTRACT Islatravir (MK-8591) is a high-potency reverse transcriptase translocation inhibitor in development for the treatment of HIV-1 infection. Data from preclinical and clinical studies suggest that ~30% to 60% of islatravir is excreted renally and that islatravir is not a substrate of renal transporters. To assess the impact of renal impairment on the pharmacokinetics of islatravir, an open-label phase 1 trial was conducted with individuals with severe renal insufficiency (RI). A single dose of islatravir 60 mg was administered orally to individuals with severe RI (estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m2) and to healthy individuals without renal impairment (matched control group; eGFR ≥90 mL/min/1.73 m2). Safety and tolerability were assessed, and blood samples were collected to measure the pharmacokinetics of islatravir and its major metabolite 4’-ethynyl-2-fluoro-2’deoxyinosine (M4) in plasma, as well as active islatravir-triphosphate (TP) in peripheral blood mononuclear cells (PBMCs). Plasma islatravir and M4 area under the concentration-time curve from zero to infinity (AUC0-∞) were ~2-fold and ~5-fold higher, respectively, in participants with severe RI relative to controls, whereas islatravir-TP AUC0-∞ was ~1.5-fold higher in the RI group than in the control group. The half-lives of islatravir in plasma and islatravir-TP in PBMCs were longer in participants with severe RI than in controls. These findings are consistent with renal excretion playing a major role in islatravir elimination. A single oral dose of islatravir 60 mg was generally well tolerated. These data provide guidance regarding administration of islatravir in individuals with impaired renal function. (This study has been registered at ClinicalTrials.gov under registration no. NCT04303156.)

[1]  Y. Yazdanpanah,et al.  Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine , 2021, Journal of acquired immune deficiency syndromes.

[2]  A. Goodey,et al.  Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial , 2021, Nature Medicine.

[3]  R. Mogg,et al.  Safety, tolerability, and pharmacokinetics of single‐ and multiple‐dose administration of islatravir (MK‐8591) in adults without HIV , 2021, Clinical and translational science.

[4]  Meihong Lin,et al.  Islatravir Is Not Expected to Be a Victim or Perpetrator of Drug-Drug Interactions via Major Drug-Metabolizing Enzymes or Transporters , 2021, Viruses.

[5]  Saijuan Zhang,et al.  Safety and Pharmacokinetics of Once-Daily Multiple-Dose Administration of Islatravir in Adults Without HIV , 2021, Journal of acquired immune deficiency syndromes.

[6]  Saijuan Zhang,et al.  A Phase 1 Study to Evaluate the Drug Interaction Between Islatravir (MK-8591) and Doravirine in Adults Without HIV , 2021, Clinical Drug Investigation.

[7]  Y. Yazdanpanah,et al.  Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial. , 2021, The lancet. HIV.

[8]  H. Mitsuya,et al.  Effects of islatravir (4'-ethynyl-2-fluoro-2'-deoxyadenosine or EFdA) on renal tubular cells and islatravir's interactions with organic anion transporters. , 2021, Journal of pharmacological sciences.

[9]  Saijuan Zhang,et al.  Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial. , 2020, The lancet. HIV.

[10]  M. Markowitz,et al.  Islatravir for the treatment and prevention of infection with the human immunodeficiency virus type 1. , 2019, Current opinion in HIV and AIDS.

[11]  S. Sarafianos,et al.  4′-Ethynyl-2-fluoro-2′-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor , 2018, Current opinion in HIV and AIDS.

[12]  C. Wyatt.  Kidney Disease and HIV Infection. , 2017, Topics in antiviral medicine.

[13]  L. Calza,et al.  HIV and kidney: a dangerous liaison. , 2017, The New Microbiologica.

[14]  S. Sarafianos,et al.  Structural basis of HIV inhibition by translocation-defective RT inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) , 2016, Proceedings of the National Academy of Sciences.

[15]  S. Sarafianos,et al.  Oral Administration of the Nucleoside EFdA (4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine) Provides Rapid Suppression of HIV Viremia in Humanized Mice and Favorable Pharmacokinetic Properties in Mice and the Rhesus Macaque , 2015, Antimicrobial Agents and Chemotherapy.

[16]  F. Salem,et al.  The changing epidemiology of HIV-related chronic kidney disease in the era of antiretroviral therapy. , 2014, Kidney international.

[17]  Andrew D. Huber,et al.  4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) Inhibits HIV-1 Reverse Transcriptase with Multiple Mechanisms* , 2014, The Journal of Biological Chemistry.

[18]  G. Verpooten.  Renal Adverse Drug Reactions , 2014 .

[19]  H. Mitsuya,et al.  Delayed Emergence of HIV-1 Variants Resistant to 4′-Ethy Nyl-2-Fluoro-2′-Deoxyadenosine: Comparative Sequential Passage Study with Lamivudine, Tenofovir, Emtricitabine and BMS-986001 , 2014, Antiviral therapy.

[20]  S. Sarafianos,et al.  Response of Simian Immunodeficiency Virus to the Novel Nucleoside Reverse Transcriptase Inhibitor 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine In Vitro and In Vivo , 2012, Antimicrobial Agents and Chemotherapy.

[21]  Marco Siccardi,et al.  Evaluation of the Mean Corpuscular Volume of Peripheral Blood Mononuclear Cells of HIV Patients by a Coulter Counter To Determine Intracellular Drug Concentrations , 2011, Antimicrobial Agents and Chemotherapy.

[22]  C. McCulloch,et al.  Risk factors for end-stage renal disease: 25-year follow-up. , 2009, Archives of internal medicine.

[23]  Christopher M. Bailey,et al.  Activity against Human Immunodeficiency Virus Type 1, Intracellular Metabolism, and Effects on Human DNA Polymerases of 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine , 2007, Antimicrobial Agents and Chemotherapy.